drugset / Trial / NCT05354843
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors. It is anticipated that approximately 37 subjects will be enrolled in the dose-escalation phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.
Timeline
- Start
- 2021-10-27
- Primary completion
- 2023-10-01
- Completion
- 2025-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ET0038 | Unknown | 10 mg | Oral |
| Subject | ET0038 | Unknown | 20 mg | Oral |
| Subject | ET0038 | Unknown | 40 mg | Oral |
| Subject | ET0038 | Unknown | 60 mg | Oral |
| Subject | ET0038 | Unknown | 80 mg | Oral |